Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer

Obstetrics & Gynecology Science
Wonkyo ShinByoung-Gie Kim

Abstract

This retrospective study is to evaluate the efficacy and toxicity of combination chemotherapy with etoposide and ifosfamide (ETI) in the management of pretreated recurrent or persistent epithelial ovarian cancer (EOC). Patients with recurrent or persistent EOC who had measurable disease and at least one chemotherapy regimen were to receive etoposide at a dose of 100 mg/m2/day intravenous (IV) on days 1 to 3 in combination with ifosfamide 1 g/m2/day IV on days 1 to 5, every 21 days. From August 2008 to August 2016, 66 patients were treated with ETI regimen. Most patients were heavily pretreated prior to ETI: 53 (80.3%) patients had received 3 or more chemotherapy regimens. The response rate (RR) of ETI chemotherapy was 18.2% and median duration of response was 6.8 months (range, 0-30). Median survival of all patients was 5 months at a median follow up of 7.2 months. Platinum-free interval (PFI) more than 6 months prior to ETI has statistically significant correlation with overall survival (OS; 9.2 vs. 5.6 months; P=0.029) and RR (34.5% vs. 5.4%; P<0.010). However, treatment free interval before ETI, number of prior chemotherapy regimen, and optimality of primary surgery did not show significant difference for RR or OS. Grade 3 o...Continue Reading

References

Oct 1, 1991·Journal of Chemotherapy·M BruzzoneN Ragni
Apr 1, 1995·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J D Hainsworth, F A Greco
Jul 25, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G AravantinosD V Skarlos
Oct 31, 2003·Oncology·M Furlanut, L Franceschi
Jun 1, 2004·American Journal of Clinical Oncology·Montaser ShaheenLawrence H Einhorn
Dec 8, 2004·Gynecologic Oncology·Mace L RothenbergDavid S Alberts
Apr 13, 2005·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·H T SeeJ J Kavanagh
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
May 6, 2011·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Jonathan A Ledermann
Jan 26, 2012·JAMA : the Journal of the American Medical Association·Kelly L BoltonUNKNOWN Cancer Genome Atlas Research Network
Aug 23, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L C HankerUNKNOWN AGO and GINECO study group
Oct 27, 2012·Asian Pacific Journal of Cancer Prevention : APJCP·Mehmet KucukonerSuleyman Buyukberber
Aug 7, 2013·Expert Opinion on Pharmacotherapy·Keiichi FujiwaraKosei Hasegawa
Apr 20, 2016·Journal of Chemotherapy·Ilan BruchimAmi Fishman
Oct 9, 2016·The New England Journal of Medicine·Mansoor R MirzaUNKNOWN ENGOT-OV16/NOVA Investigators
Dec 10, 2016·The Journal of Obstetrics and Gynaecology Research·Yuji TakeiHiroyuki Fujiwara
Dec 29, 2016·Best Practice & Research. Clinical Obstetrics & Gynaecology·Kate Webber, Michael Friedlander

❮ Previous
Next ❯

Citations

Aug 24, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Shufeng DuanCaixia Chen

❮ Previous
Next ❯

Methods Mentioned

BETA
imaging techniques

Software Mentioned

SPSS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.